Biotechnology
The World's Largest 36,000L Biomanufacturing Line Using Single-use Bioreactors Launches GMP Operation at WuXi Biologics
* Greatly increase the company's current capacity to 90,000L and enable WuXi Biologics to initiate any project within four weeks * Offer flexible large-scale manufacturing services by implementing Scale-out strategy WUXI, China, Feb. 9, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.H...
Proxima Ventures and Co-win Ventures invest in Bioelectronica® Corporation to accelerate pharmaceutical discovery and development
RENO, Nev., Feb. 9, 2021 /PRNewswire/ -- Bioelectronica Corporation ("Bioelectronica") today announced the closing of an investment by Proxima Ventures and Co-win Ventures to advance the company's innovations in digital biochemistry, from novel assay development to scalable electrofluidics. The ...
Longevity Acquisition Corporation Announces 4D pharma Clinical Trial Collaboration and Supply Agreement for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that onFebruary 8, 2021, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Liv...
Inova Appoints Claude Basset as Chief Product Officer
LYON, France, Feb. 8, 2021 /PRNewswire/ -- Inova, the market-leading partnering platform for the pharmaceutical and biotech industry, today announced that Claude Basset has joined their leadership team as Chief Product Officer. Inova is a French Tech success story that, now in its 10th year, ha...
Orpha Labs AG Initiates Compassionate Use Program for ORL-101 in Leukocyte Adhesion Deficiency Type II (LAD-II)
First Patient to Receive ORL-101 in Israel This Week BAAR, Switzerland, Feb. 8, 2021 /PRNewswire/ -- Orpha Labs AG today announced its compassionate use program to make ORL-101 available to physicians providing care for Leukocyte Adhesion Deficiency Type II (LAD-II) patients. ORL-101 is a novel ...
I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.
SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced multiple clinical advancements for its proprieta...
I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China
SHANGHAI and GAITHERSBURG, Md., Feb. 4, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in a phase 2 clinic...
Covid-19 Drug Duo Achievements: GoldenBiotech's New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries
TAIPEI, Feb.4, 2021 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132)("GoldenBiotech"), a leading Taiwanese biopharmaceutical company, announced that it has made two achievements for its Covid-19 new drug candidate Antroquinonol® (HOCENA®): receiving positive response after DMC review in Pha...
Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences' Toripalimab
BOSTON and BEIJING, Feb. 3, 2021 /PRNewswire/ -- Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with Junshi Biosciences' anti-PD-1 antibody Toripalimab (TUOYI®)...
Ping An Healthcare and Technology Company Limited posts revenue of RMB 6,866 million in 2020
Launches comprehensive strategic upgrade Revenue from online medical services, its core business, grows 82.4% year-on-year HONG KONG, Feb. 3, 2021 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor"; Stock Code: 01833.HK), a leading internet healthcare se...
Dyadic and TurtleTree Scientific enter strategic partnership
SAN FRANCISCO, Feb. 2, 2021 /PRNewswire/ -- Dyadic International, Inc.
Ascentage Pharma Released Preclinical Results of MDM2-p53 Inhibitor APG-115 in an Oral Presentation at WCLC 2020, Demonstrating Therapeutic Potential in STK11-Mutant Non-Small Cell Lung Cancer
SUZHOU, China and ROCKVILLE, Md., Feb. 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the company recently released ...
Inmagene launched U.S. subsidiary; Dr. Jean-Louis Saillot joined the company.
SAN DIEGO, Calif. and SHANGHAI, Feb. 2, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a leading biotech company focused on immunology-related therapeutic areas, today announced the launch of its wholly-owned subsidiary inSan Diego. Jean-Louis Saillot, MD has joined the company a...
Crafoord Laureate discovered the explanation for mysterious fevers
STOCKHOLM, Feb. 1, 2021 /PRNewswire/ -- Dan Kastner, USA, has described an entirely new group of rare autoinflammatory diseases. His discoveries have brought new knowledge and led to the development of effective treatments. The Royal Swedish Academy of Sciences is awarding him this year's Crafoor...
Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate
* Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax's CpG 1018 plus alumin the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. * The Coalition for Epid...
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
* Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial * Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy pot...
Seegene develops world first COVID-19 variant test capable of identifying origins of virus variants
* SEEGENE ROLLS OUT FIRST COVID-19 MUTANT IDENTIFICATION TEST * COVID-19 TEST MANUFACTURER CONTINUES TRACKING VARIANTS * S. KOREAN FIRM COMMITTED TO WORKING WITH GOVERNMENTS SEOUL, South Korea, Feb. 1, 2021 /PRNewswire/ -- South Korea's biotechnology firm Seegene (KQ096530) said Monday it ...
RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib
TEL AVIV, Israel and RALEIGH, N.C., Jan. 29, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
Ascentage Pharma Announces the Fifth Orphan Drug Designation Granted to Bcl-2 Inhibitor APG-2575 by the US FDA, and the Tenth Obtained by the Company
SUZHOU, China and ROCKVILLE, Md., Jan. 29, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug A...
Alfasigma to expand its digital footprint
Online doctorAsyou, a web platform entirely dedicated to physicians The website optimizes research on the most important and autoritative medical databases such as Pubmed, ICTRP and ClinicalTrials.gov. An entirely new area presents online courses for physicians on several different topics BOLO...
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00